Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical
about
Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.Identification of clinically used drugs that activate pregnane X receptorsUpregulation of CYP 450s expression of immortalized hepatocyte-like cells derived from mesenchymal stem cells by enzyme inducers.Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implicationsEvaluation of metabolism-mediated herb-drug interactions.Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.BDE47 induces rat CYP3A1 by targeting the transcriptional regulation of miR-23b.Sex differences in the expression of hepatic drug metabolizing enzymes.Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem.Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.Three-dimensionally engineered biomimetic tissue models for in vitro drug evaluation: delivery, efficacy and toxicity.Evaluation of pregnane X receptor (PXR)-mediated CYP3A4 drug-drug interactions in drug development.Utilization of glutathione S-transferase Mu 1- and Theta 1-null mice as animal models for absorption, distribution, metabolism, excretion and toxicity studies.The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications.Advantages of cell-based high-volume screening assays to assess nuclear receptor activation during drug discovery.Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.Drug metabolism and drug interactions: potential application to antituberculosis drugs.Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.Evaluation of a novel PXR-knockout in HepaRG™ cells.Approaches towards molecular amplification for sensing.Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.The utility of cold-preserved human hepatocytes in studies on cytochrome P450 induction and hepatic drug transport.Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor.In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450."Drugs on oxygen": an update and perspective on the role of cytochrome P450 testing in pharmacology.Effect of MRSA on CYP450: dynamic changes of cytokines, oxidative stress, and drug-metabolizing enzymes in mice infected with MRSA.Effects of Hypericum perforatum hydroalcoholic extract, hypericin, and hyperforin on cytotoxicity and CYP3A4 mRNA expression in hepatic cell lines: a comparative studyPerfusion of 3D encapsulated hepatocytes-A synergistic effect enhancing long-term functionality in bioreactors
P2860
Q30664468-F20AF376-5AD1-4024-837B-77A9D8400EF6Q33725126-4004E14D-D47D-49F8-B545-19D5114FFCAAQ34035977-EB6EDA42-F572-4E4D-A133-2306AF3FB2CDQ34099814-29433493-4B72-495B-8FE7-650356AA3F9EQ34238039-A85DA2EA-EC77-44B2-9E26-EB9E1C334C17Q35174116-976E1EE8-38DE-42B9-8DB2-962681B45EACQ37121662-514DDD3B-52E1-4747-B7E3-3099C973BD9AQ37193395-87AD6559-CEA3-456F-8A53-86CD13ECC98BQ37268108-5C2F8631-7693-4BC6-9B64-F6C6BAD22B7DQ37592262-B65CA1D2-070F-44BE-AEC0-17BB1C54B7EDQ37607932-0DEC4F7D-D601-4785-9ABC-915898A15716Q38071670-BE94FFC9-9644-4D0F-AC98-7811813AC242Q38074989-AED7D53F-5F03-4C11-B4A2-D66677998E95Q38090712-201DFEDE-A7FC-4A4E-8494-1D909EB8A93FQ38128592-9FF51675-F273-4DA9-91A7-316600F42F1BQ38211210-DBC3A139-DD90-40E2-9F9B-DA62742571F5Q38255685-44011059-CE4C-4F78-AC52-6EDE31F401BBQ38502286-B49B193F-2C06-4C10-95F4-87E970C797B6Q38621024-18185ED1-27B5-4074-AFC6-46DF997DE083Q38634986-DEFD4AD0-9152-4A7A-B1C9-D3C32F24DE92Q38742139-10EAB990-9F8F-42E7-82F8-0FF6676D0E8DQ38818221-4F12FE2B-B14E-41EC-84E1-6F751A29ACB0Q40192653-CE57B968-CB21-4704-ABE4-42431F22EAD5Q42436904-2804899C-E3E8-48BA-8DA0-700E927574D2Q50028945-DAF4ED0E-AE9F-4010-B2F5-5878B3A83585Q50557160-233AD95D-6671-4587-A3E6-2658C9CC415FQ51557998-8297C43F-6CEA-4C06-90C7-4580AAADBD88Q52680599-0D3F9DDD-029A-4BC4-8DAD-D565362EE3E3Q57888889-B8A79249-B54C-413C-B645-D0E31F07E1C9Q58754027-C994C6FD-67F2-4156-8F1C-DC7695A14B33
P2860
Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current industrial practices i ...... tion: preclinical and clinical
@en
Current industrial practices i ...... ion: preclinical and clinical.
@nl
type
label
Current industrial practices i ...... tion: preclinical and clinical
@en
Current industrial practices i ...... ion: preclinical and clinical.
@nl
prefLabel
Current industrial practices i ...... tion: preclinical and clinical
@en
Current industrial practices i ...... ion: preclinical and clinical.
@nl
P2093
P2860
P1433
P1476
Current industrial practices i ...... tion: preclinical and clinical
@en
P2093
Gillian Wallace
Jasminder Sahi
Michael Sinz
P2860
P2888
P304
P356
10.1208/S12248-008-9037-4
P407
P577
2008-06-01T00:00:00Z
P5875
P6179
1006702898